AI In Biotechnology Market Report 2026

AI In Biotechnology Market Overview

• AI In Biotechnology market size has reached to $5.52 billion in 2025 • Expected to grow to $16.32 billion in 2030 at a compound annual growth rate (CAGR) of 24.1% • Growth Driver: Increasing Adoption Of AI Driving Growth In The Market Due To Advancements In Technology • Market Trend: Revolutionizing Antibody Discovery Through Advanced AI-Powered Biotech Innovation • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under AI In Biotechnology Market?

Artificial intelligence (AI) in biotechnology refers to the use of machine learning and data-driven algorithms to analyze biological data and accelerate research. It helps in drug discovery, genomics, diagnostics, and personalized medicine by identifying patterns and predicting outcomes. AI enhances efficiency, reduces costs, and enables deeper insights into complex biological systems, driving innovation in healthcare and life sciences. The main components of AI in biotechnology are software, hardware, and services. Software in artificial intelligence (AI) in biotechnology refers to advanced computational tools and algorithms designed to analyze biological data, model complex biological systems, and accelerate processes such as drug discovery, genomics, and precision medicine. It is used in applications such as drug discovery and development, clinical trials and optimization, medical imaging, diagnostics, and others catering to end users, including pharmaceutical companies, biotechnology companies, academic and research institutes, healthcare providers, contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and others.

What Is The AI In Biotechnology Market Growth Forecast?

The AI in biotechnology market size is expected to see exponential growth in the next few years. It will grow to $16.32 billion in 2030 at a compound annual growth rate (CAGR) of 24.1%. The growth in the forecast period can be attributed to advancements in machine learning algorithms, expansion of precision medicine, increasing AI investment in life sciences, demand for cost efficient drug development, integration of AI with laboratory automation. Major trends in the forecast period include AI driven drug discovery, predictive genomics analysis, automated clinical trial optimization, AI enabled diagnostics, data centric personalized medicine.

Global AI In Biotechnology Market Segmentation

1) By Component: Software, Hardware, Services 2) By Application: Drug Discovery And Development, Clinical Trials And Optimization, Medical Imaging, Diagnostics, Other Applications 3) By End User: Pharmaceutical Companies, Biotechnology Companies, Academic And Research Institutes, Healthcare Providers, Contract Research Organization (CRO) And Contract Development And Manufacturing Organization (CDMO), Other End Users Subsegments: 1) By Software: AI-Powered Data Analytics Tools, Machine Learning Algorithms, Bioinformatics Software, Drug Discovery Platforms, Clinical Trial Management Software 2) By Hardware: High-Performance Computing (HPC) Systems, AI-Integrated Imaging Devices, Data Storage Solutions, Laboratory Automation Equipment, Wearable Health Monitoring Devices 3) By Services: AI Implementation And Integration Services, Consulting And Training Services, Cloud-Based AI Solutions, Maintenance And Support Services, Custom AI Model Development

What Is The Driver Of The AI In Biotechnology Market?

The increasing adoption of AI is expected to propel the growth of the AI in biotechnology market going forward. Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems, to perform tasks such as learning, reasoning, and problem-solving. The increasing adoption of artificial intelligence (AI) is driven by its ability to enhance efficiency, accuracy, and decision-making across industries, demonstrated by its capacity to automate complex data analysis with consistent precision. In the biotechnology sector, artificial intelligence (AI) plays a positive role by accelerating drug discovery, optimizing research processes, and enabling advanced predictive modeling for improved healthcare outcomes. For instance, in October 2024, according to the Department for Science, Innovation & Technology (DSIT), a UK-based government agency, the growing adoption of artificial intelligence (AI) in 2023 is reflected in a 17% rise in the number of AI companies (+543), a 34% surge in AI-related revenues (+£3.6 billion), a 29% increase in employment (+14,500), and a nearly 57% jump in gross value added (GVA) (+£2.1 billion) compared to the 2022 report. Therefore, the increasing adoption of AI is driving the growth of the AI in biotechnology industry.

Key Players In The Global AI In Biotechnology Market

Major companies operating in the AI in biotechnology market are Google LLC, Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., International Business Machines Corporation (IBM), Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc, Abbott Laboratories, Novartis AG, Roivant Sciences Ltd., Gilead Sciences Inc., NVIDIA Corporation, Amgen Inc., Novo Nordisk A/S, Merck KGaA, Biogen Inc., CareDx Inc., Clario Inc., BenevolentAI Limited, Recursion Pharmaceuticals Inc., Insilico Medicine Inc., Genesis Therapeutics Inc.

Global AI In Biotechnology Market Trends and Insights

Major companies operating in the AI in biotechnology market are focusing on developing technological advancements, such as AI-powered antibody discovery platforms, to gain a competitive edge in the market. An AI-powered antibody discovery platform is a technology-driven system that uses artificial intelligence to rapidly identify and optimize therapeutic antibodies, enabling faster, more cost-effective drug development and improved biopharmaceutical outcomes. For instance, in February 2023, AION Labs, an Israel-based venture studio, launched DenovAI, a platform designed for the de novo discovery of therapeutic antibodies. This cutting-edge solution combines machine learning with computational biophysics to identify high-affinity antibody candidates with enhanced precision, broader sequence diversity, and significantly reduced development timelines. DenovAI marks a transformative advancement in biotechnology, enabling faster, more cost-effective drug discovery and improving the chances of clinical success across a wider spectrum of diseases.

What Are Latest Mergers And Acquisitions In The AI In Biotechnology Market?

In February 2025, Incyte Corporation, a US-based biopharmaceutical company, partnered with Genesis Therapeutics Inc. to leverage the transformative power of artificial intelligence (AI) to enhance drug development efficiency. This collaboration aims to integrate Incyte’s expertise in drug discovery with Genesis Therapeutics’ proprietary AI platform to accelerate the identification and optimization of innovative small molecule candidates for selected therapeutic targets. Genesis Therapeutics Inc. is a US-based, AI-driven biotechnology company dedicated to advancing drug discovery through cutting-edge technology.

Regional Insights

North America was the largest region in the AI in biotechnology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the AI In Biotechnology Market?

The AI in biotechnology market consists of revenues earned by entities providing services such as genomics analysis, precision medicine development, biomanufacturing optimization, and AI-driven diagnostics. The market value includes the value of related goods sold by the service provider or included within the service offering. The AI in biotechnology market also includes sales of bioinformatics tools, automation systems, and AI-integrated laboratory equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the AI In Biotechnology Market Report 2026?

The ai in biotechnology market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ai in biotechnology industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.